Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, December 22 '24)

 


    Am J Med

  1. HAWLEY HB
    Long COVID: Clinical Findings, Pathology, and Endothelial Molecular Mechanisms.
    Am J Med. 2025;138:91-97.
    PubMed         Abstract available

  2. HAYES LD, Sanal-Hayes NEM, Mclaughlin M, Berry ECJ, et al
    People with Long Covid and ME/CFS Exhibit Similarly Impaired Balance and Physical Capacity: A Case-Case-Control Study.
    Am J Med. 2025;138:140-147.
    PubMed         Abstract available

  3. MCLAUGHLIN M, Cerexhe L, Macdonald E, Ingram J, et al
    A Cross-Sectional Study of Symptom Prevalence, Frequency, Severity, and Impact of Long COVID in Scotland: Part I.
    Am J Med. 2025;138:121-130.
    PubMed         Abstract available

  4. HONDA H, Takamatsu A, Miwa T, Tabuchi T, et al
    Prolonged Symptoms after COVID-19 in Japan: A Nationwide Survey of the Symptoms and Their Impact on Patients' Quality of Life.
    Am J Med. 2025;138:98-107.
    PubMed         Abstract available

  5. BAILEY J, Lavelle B, Miller J, Jimenez M, et al
    Multidisciplinary Center Care for Long COVID Syndrome-A Retrospective Cohort Study.
    Am J Med. 2025;138:108-120.
    PubMed         Abstract available

  6. XUEREB RA, Borg M, Vella K, Gatt A, et al
    Long COVID Syndrome: A Case-Control Study.
    Am J Med. 2025;138:131-139.
    PubMed         Abstract available

  7. HASLAM A, Prasad V
    Comparability of Control and Comparison Groups in Studies Assessing Long COVID.
    Am J Med. 2025;138:148-152.
    PubMed         Abstract available


    Ann Intern Med

  8. VASSILOPOULOS S, Mylonakis E
    After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
    Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
    PubMed         Abstract available


    Antiviral Res

  9. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
    Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
    Antiviral Res. 2024;232:106038.
    PubMed         Abstract available

  10. SASAKI J, Sato A, Sasaki M, Okabe I, et al
    X-206 exhibits broad-spectrum anti-beta-coronavirus activity, covering SARS-CoV-2 variants and drug-resistant isolates.
    Antiviral Res. 2024 Nov 19:106039. doi: 10.1016/j.antiviral.2024.106039.
    PubMed         Abstract available

  11. WELCH SR, Bilello JP, Carter K, Delang L, et al
    Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.
    Antiviral Res. 2024;232:106037.
    PubMed         Abstract available

  12. NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al
    Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.
    Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026.
    PubMed         Abstract available


    Arch Virol

  13. ZALI M, Sadat Larijani M, Bavand A, Moradi L, et al
    Circulatory microRNAs as potential biomarkers for different aspects of COVID-19.
    Arch Virol. 2024;170:8.
    PubMed         Abstract available

  14. NAVARRO-LOPEZ R, Valdez-Gomez HE, Zalapa-Hernandez M, Solis-Hernandez M, et al
    An epizootic of highly pathogenic avian influenza virus H7N3 in a Mexican ecological reserve.
    Arch Virol. 2024;170:6.
    PubMed         Abstract available

  15. GUNASEKARA E, Hair-Bejo M, Aini I, Omar AR, et al
    Molecular characterisation of novel reassortants of the G57 genotype of low-pathogenic avian influenza H9N2 virus isolated from poultry farms in Malaysia.
    Arch Virol. 2024;170:3.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  16. HOSOKAWA K, Ohmori H
    Digital reverse transcription PCR using a simple poly(dimethylsiloxane) microwell array chip for detection of SARS-CoV-2.
    Biochem Biophys Res Commun. 2024;741:151070.
    PubMed         Abstract available


    BMC Pediatr

  17. LIN F, Liang JL, Guan ZX, Wu M, et al
    Hospitalized children with influenza A before, during and after COVID-19 pandemic: a retrospective cohort study.
    BMC Pediatr. 2024;24:828.
    PubMed         Abstract available


    BMJ

  18. FLYNN SG, Park RS, Jena AB, Staffa SJ, et al
    Coaching inexperienced clinicians before a high stakes medical procedure: randomized clinical trial.
    BMJ. 2024;387:e080924.
    PubMed         Abstract available

  19. BONCYK C, Rolfsen ML, Richards D, Stollings JL, et al
    Management of pain and sedation in the intensive care unit.
    BMJ. 2024;387:e079789.
    PubMed         Abstract available


    Cell

  20. ROSEN LE, Tortorici MA, De Marco A, Pinto D, et al
    A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification.
    Cell. 2024;187:7196-7213.
    PubMed         Abstract available


    Epidemiol Infect

  21. ZHENG C, Yu FY, Chan PS, Sun F, et al
    Receiving three doses of inactivated or mRNA COVID-19 vaccines was associated with lower odds of long COVID symptoms among people with a history of SARS-CoV-2 infection in Hong Kong, China: a cross-sectional survey study.
    Epidemiol Infect. 2024;152:e166.
    PubMed         Abstract available

  22. WANG S, Yan J, Song M, Xue Z, et al
    Development of a nomogram for high antibody titre of COVID-19 convalescent plasma.
    Epidemiol Infect. 2024;152:e167.
    PubMed         Abstract available


    Eur J Epidemiol

  23. IOANNIDIS JPA
    Differential risk of healthcare workers versus the general population during outbreak, war and pandemic crises.
    Eur J Epidemiol. 2024;39:1211-1219.
    PubMed         Abstract available

  24. NARAYANAN MK, Dodgeon B, Katsoulis M, Ploubidis GB, et al
    How to mitigate selection bias in COVID-19 surveys: evidence from five national cohorts.
    Eur J Epidemiol. 2024;39:1221-1227.
    PubMed         Abstract available


    J Clin Microbiol

  25. GRENINGER AL, Larcena A, Patel A, Webster B, et al
    Prospective, multi-site evaluation of the Cepheid Xpert Xpress CoV-2 plus test on nasal and nasopharyngeal swabs.
    J Clin Microbiol. 2024;62:e0121924.
    PubMed         Abstract available


    J Gen Virol

  26. KRISHNA B, Metaxaki M, Perera M, Wills M, et al
    Comparison of different T cell assays for the retrospective determination of SARS-CoV-2 infection.
    J Gen Virol. 2024;105.
    PubMed         Abstract available

  27. ALNAJJAR S, Larios-Mora A, Van-Geelen A, Gallup J, et al
    Therapeutic efficacy of JNJ-49214698, an RSV fusion inhibitor, in RSV-infected neonatal lambs.
    J Gen Virol. 2024;105:002056.
    PubMed         Abstract available


    J Infect

  28. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    PubMed         Abstract available

  29. CHOW KN, Tsang YW, Chan YH, Telaga SA, et al
    The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis.
    J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358.
    PubMed         Abstract available

  30. REN Z, Yang M, Su G, Qian G, et al
    Real-world effectiveness and safety of Azvudine in hospitalized patients with SARS-CoV-2 infection: a multicenter, retrospective cohort study.
    J Infect. 2024 Nov 17:106355. doi: 10.1016/j.jinf.2024.106355.
    PubMed         Abstract available

  31. MCLEOD C, Dymock M, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.
    J Infect. 2024 Nov 14:106346. doi: 10.1016/j.jinf.2024.106346.
    PubMed         Abstract available

  32. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    PubMed         Abstract available

  33. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed         Abstract available

  34. CITRON MP, Zang X, Leithead A, Meng S, et al
    Evaluation of a non-nucleoside inhibitor of the RSV RNA-dependent RNA polymerase in translatable animals models.
    J Infect. 2024;89:106325.
    PubMed         Abstract available

  35. KUMAR NP, Balaji S, Devi PG, Ramraj B, et al
    Inflammatory Cytokine Responses in Pediatric tuberculosis with or without SARS-CoV-2 seropositivity.
    J Infect. 2024 Oct 17:106314. doi: 10.1016/j.jinf.2024.106314.
    PubMed         Abstract available

  36. WEI X, Wang L, Li M, Qi J, et al
    Novel imported clades accelerated the RSV surge in Beijing, China, 2023-2024.
    J Infect. 2024 Oct 17:106321. doi: 10.1016/j.jinf.2024.106321.
    PubMed         Abstract available

  37. MEIRMAN TD, Shapira B, Balicer RD, Rokach L, et al
    Trends of Common Laboratory Biomarkers after SARS-CoV-2 Infection.
    J Infect. 2024 Oct 16:106318. doi: 10.1016/j.jinf.2024.106318.
    PubMed         Abstract available

  38. CHEN X, Meng X, Wu Q, Lim WW, et al
    Assessment of Neutralizing Antibody Response as a Correlate of Protection against Symptomatic SARS-CoV-2 Infections after Administration of two doses of the CoronaVac inactivated COVID-19 Vaccine: A Phase III Randomized Controlled Trial.
    J Infect. 2024 Oct 16:106315. doi: 10.1016/j.jinf.2024.106315.
    PubMed         Abstract available

  39. MADSEN AMR, Gehrt L, Schaltz-Buchholzer F, Moller S, et al
    Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: a randomised clinical trial.
    J Infect. 2024 Oct 16:106319. doi: 10.1016/j.jinf.2024.106319.
    PubMed         Abstract available

  40. MARCHESE AM, Fries L, Beyhaghi H, Vadivale M, et al
    Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines.
    J Infect. 2024 Oct 15:106317. doi: 10.1016/j.jinf.2024.106317.
    PubMed         Abstract available

  41. LI Y, Zhang X, Yi J, Chen Y, et al
    Synergistic evolution: the dynamic adaptation of SARS-CoV-2 and human protective immunity in the real world.
    J Infect. 2024 Oct 9:106310. doi: 10.1016/j.jinf.2024.106310.
    PubMed         Abstract available

  42. ALOISIO GM, Nagaraj D, Murray AM, Schultz EM, et al
    Infant-derived human nasal organoids exhibit relatively increased susceptibility, epithelial responses, and cytotoxicity during RSV infection.
    J Infect. 2024;89:106305.
    PubMed         Abstract available

  43. AMARILLA-IRUSTA A, Zenarruzabeitia O, Sevilla A, Sanda V, et al
    CD151 identifies a NK cell subset that is enriched in COVID-19 patients and correlates with disease severity.
    J Infect. 2024 Oct 5:106304. doi: 10.1016/j.jinf.2024.106304.
    PubMed         Abstract available

  44. FYLES M, Overton CE, Ward T, Bennett E, et al
    Modelling multiplex testing for outbreak control.
    J Infect. 2024 Oct 1:106303. doi: 10.1016/j.jinf.2024.106303.
    PubMed         Abstract available

  45. AKSU MD, van der Ent T, Zhang Z, Riza AL, et al
    Regulation of plasma soluble receptors of TNF and IL-1 in patients with COVID-19 differs from that observed in sepsis.
    J Infect. 2024 Sep 30:106300. doi: 10.1016/j.jinf.2024.106300.
    PubMed         Abstract available

  46. DEHLIA A, Guthridge MA
    The persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Infect. 2024 Sep 29:106297. doi: 10.1016/j.jinf.2024.106297.
    PubMed         Abstract available

  47. BENNETT C, Hoosain Z, Koen A, Lalloo U, et al
    Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in South African People Living With and Without HIV-1 Infection: A Phase 2 Randomised Trial.
    J Infect. 2024 Sep 27:106285. doi: 10.1016/j.jinf.2024.106285.
    PubMed         Abstract available

  48. MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
    J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286.
    PubMed         Abstract available


    J Infect Dis

  49. HAMMERTON SM, Billings WZ, Hemme H, Ross TM, et al
    Estimating standard-dose and high-dose Fluzone vaccine efficacies for influenza A based on HAI titers.
    J Infect Dis. 2024 Dec 13:jiae615. doi: 10.1093.
    PubMed         Abstract available

  50. TANG Y, Boribong BP, Swank ZN, Demokritou M, et al
    COVID-19 mRNA vaccines induce robust levels of IgG but limited amounts of IgA within the oronasopharynx of young children.
    J Infect Dis. 2024 Sep 10:jiae450. doi: 10.1093.
    PubMed         Abstract available

  51. JANES H, Fisher LH, Kee JJ, Parameswaran L, et al
    Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
    J Infect Dis. 2024 Sep 3:jiae400. doi: 10.1093.
    PubMed         Abstract available

  52. ANDERSON EJ, Tippett A, Begier E, Gibson T, et al
    Relative Contribution of Diagnostic Testing to the Diagnosis of Respiratory Syncytial Virus in Hospitalized Adults in the United States.
    J Infect Dis. 2024;230:1342-1351.
    PubMed         Abstract available

  53. DOTY B, Ghaswalla P, Bohn RL, Stoszek SK, et al
    Incidence of RSV in Adults: A Comprehensive Review of Observational Studies and Critical Gaps in Information.
    J Infect Dis. 2024;230:e1182-e1201.
    PubMed         Abstract available

  54. ANDRES C, Perramon-Malavez A, Creus-Costa A, Gatell A, et al
    Respiratory Viral Coinfections in Pediatric Patients in the Primary Care Setting: A Multicenter Prospective Study Within the COPEDICAT Network.
    J Infect Dis. 2024;230:1337-1341.
    PubMed         Abstract available


    J Virol

  55. PATINO-GALINDO J, Garcia-Sastre A, Kuhn JH, Rabadan R, et al
    Recombination across distant coronavirid species and genera is a rare event with distinct genomic features.
    J Virol. 2024 Nov 19:e0110024. doi: 10.1128/jvi.01100.
    PubMed         Abstract available

  56. XIONG Y, Tao K, Li T, Zhou Y, et al
    Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein.
    J Virol. 2024;98:e0153624.
    PubMed         Abstract available

  57. NEAL HE, Barrett CT, Edmonds K, Moncman CL, et al
    Examination of respiratory syncytial virus fusion protein proteolytic processing and roles of the P27 domain.
    J Virol. 2024;98:e0163924.
    PubMed         Abstract available

  58. CHEN D, Zhang W, Xiao B, Xu B, et al
    Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
    J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
    PubMed         Abstract available

  59. TAKAHASHI T, Amarbayasgalan S, Ueno S, Sugiura Y, et al
    Lethal model for respiratory syncytial virus infection using C57BL/6 mice.
    J Virol. 2024;98:e0177224.
    PubMed         Abstract available

  60. STEIN SC, Hansen G, Ssebyatika G, Stroh LJ, et al
    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
    J Virol. 2024 Nov 4:e0122324. doi: 10.1128/jvi.01223.
    PubMed         Abstract available

  61. PARRY RH, Lytras S, Petrone ME, Wille M, et al
    No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
    J Virol. 2024 Nov 4:e0146824. doi: 10.1128/jvi.01468.
    PubMed         Abstract available


    J Virol Methods

  62. ASHLEY CL, Bloul M, Alca S, Smith L, et al
    Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variants.
    J Virol Methods. 2025;332:115073.
    PubMed         Abstract available

  63. DA SILVA JG, Arruk VG, Veiga GRLD, Sousa LVA, et al
    Quantitative and qualitative analysis of seroconversion after one year of vaccination with inactivated SARS-CoV-2 vaccine (CoronaVac(R)) in healthcare workers: Cross-sectional analytical study.
    J Virol Methods. 2025;332:115067.
    PubMed         Abstract available

  64. FIBRIANI A, Naisanu K, Yamahoki N, Kinanti DR, et al
    Development of polyclonal chicken egg yolk immunoglobulin Y (IgY) antibodies targeting SARS-CoV-2 multi-epitope antigen.
    J Virol Methods. 2025;331:115062.
    PubMed         Abstract available

  65. YAMAZAKI Y, Tanaka R, Castillo G, Macalanda AMC, et al
    Development of a concentration method for simple and sensitive detection of SARS-CoV-2 in saliva using a magnetic nanoparticle kit.
    J Virol Methods. 2025;331:115059.
    PubMed         Abstract available

  66. MDUNYELWA A, Seema C, Mabaso A, Mlambo K, et al
    Evaluation of the Seegene Allplex RV master assay for one-step simultaneous detection of eight respiratory viruses in nasopharyngeal specimens.
    J Virol Methods. 2025;331:115042.
    PubMed         Abstract available


    JAMA

  67. TADROUS M, Callaway Kim K, Hernandez I, Rothenberger SD, et al
    Differences in Drug Shortages in the US and Canada.
    JAMA. 2024 Oct 31. doi: 10.1001/jama.2024.17688.
    PubMed         Abstract available


    Lancet

  68. DZAU VJ, Laitner MH, Shambaugh EL
    Strategic imperatives for health in the USA: a roadmap for the incoming presidential administration.
    Lancet. 2024;404:2371-2379.
    PubMed         Abstract available


  69. The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024;404:2314-2340.
    PubMed         Abstract available


    Minerva Pediatr (Torino)

  70. MARIANI A, Tiryaki S, Harms M, Orlov V, et al
    What we learned from the COVID-19 first wave: a survey from Young Pediatric Urology Committee (YPUC) from ESPU.
    Minerva Pediatr (Torino). 2024;76:735-742.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  71. ABDIRIZAK F, Winn AK, Parikh R, Scobie HM, et al
    Surveillance of Human Adenovirus Types and the Impact of the COVID-19 Pandemic on Reporting - United States, 2017-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1136-1141.
    PubMed         Abstract available


    PLoS Biol

  72. KUCHARSKI AJ
    Controlling minor outbreaks is necessary to prepare for major pandemics.
    PLoS Biol. 2024;22:e3002945.
    PubMed         Abstract available


    PLoS One

  73. SOEORG H, Abroi A, Pall T, Dotsenko L, et al
    Dynamics of SARS-CoV-2 lineages in children and adults in 2021 and 2022.
    PLoS One. 2024;19:e0316213.
    PubMed         Abstract available

  74. CHAE SW, Hara N, Shiroiya HR, Chen J, et al
    Being vulnerable with viewers: Exploring how medical YouTubers communicated about COVID-19 with the public.
    PLoS One. 2024;19:e0313857.
    PubMed         Abstract available

  75. GUERRERIO AL, Mateja A, MacCarrick G, Fintzi J, et al
    Cardiovascular complications in vascular connective tissue disorders after COVID-19 infection and vaccination.
    PLoS One. 2024;19:e0315499.
    PubMed         Abstract available

  76. ZAMIR MT, Ullah F, Tariq R, Bangyal WH, et al
    Machine and deep learning algorithms for sentiment analysis during COVID-19: A vision to create fake news resistant society.
    PLoS One. 2024;19:e0315407.
    PubMed         Abstract available

  77. WEBSTER M, Manoukian S, McKendrick JH, Biosca O, et al
    Exploring the gender gap in young adult mental health during COVID-19: Evidence from the UK.
    PLoS One. 2024;19:e0305680.
    PubMed         Abstract available

  78. SULTANA KAKOLY N, Hasan SMK, Hoque MM, Ratul RH, et al
    Sociodemographic factors, clinical characteristics, outcomes and short-term follow-up in COVID-19 patients with new onset hyperglycemia and pre-existing diabetes on admission in a tertiary-care hospital in Bangladesh.
    PLoS One. 2024;19:e0311508.
    PubMed         Abstract available

  79. SAMBEL AYKUTLU M, Aykutlu HC, Ozveren M, Garip R, et al
    Digital media use and its effects on digital eye strain and sleep quality in adolescents: A new emerging epidemic?
    PLoS One. 2024;19:e0314390.
    PubMed         Abstract available

  80. SU H, Yang PL, Eaton TL, Valley TS, et al
    Cognition, function, and mood post-COVID-19: Comparative analysis using the health and retirement study.
    PLoS One. 2024;19:e0315425.
    PubMed         Abstract available

  81. LE GOFF D, Perraud G, Leon M, Aujoulat P, et al
    Innovative population-based strategies for primary prevention of cardiovascular disease: A 2-year randomised control trial evaluating behavioral change led by community champions versus brief advice.
    PLoS One. 2024;19:e0314748.
    PubMed         Abstract available

  82. CHANG H, Li S, Ke X, Zhou Z, et al
    Differences in emergency hospitalization trauma patients during and after the COVID-19 pandemic.
    PLoS One. 2024;19:e0315416.
    PubMed         Abstract available

  83. BOUTHILLIER ME, Farmer Y, Calderon Ramirez C, Downar J, et al
    Public perspectives on COVID-19 triage protocols for access to critical care in extreme pandemic context.
    PLoS One. 2024;19:e0314460.
    PubMed         Abstract available

  84. SARKAR J
    To test or not to test? A new behavioral epidemiology framework for COVID-19.
    PLoS One. 2024;19:e0309423.
    PubMed         Abstract available

  85. MOBARAK H, Haddad C, Salameh P, Towair E, et al
    The relationship between self-determination and burnout: Mental health outcomes in medical residents.
    PLoS One. 2024;19:e0308897.
    PubMed         Abstract available

  86. SANTARPIA JL, Lau J, Shom D, Ratnesar-Shumate SA, et al
    Association between in situ ventilation and human-generated aerosol exposure in meatpacking plants during the COVID-19 pandemic.
    PLoS One. 2024;19:e0314856.
    PubMed         Abstract available

  87. BEIG M, Parvizi E, Navidifar T, Bostanghadiri N, et al
    Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.
    PLoS One. 2024;19:e0311124.
    PubMed         Abstract available

  88. DJAILEB A, Parker MF, Lavallee E, Stuible M, et al
    Longitudinal determination of seroprevalence and immune response to SARS-CoV-2 in a population of food and retail workers through decentralized testing and transformation of ELISA datasets.
    PLoS One. 2024;19:e0314499.
    PubMed         Abstract available

  89. ZHENG J, Li B, Jia L, Zhang J, et al
    Tumorigenicity decrease in Bcl-xL deficient MDCK cells ensuring the safety for influenza vaccine production.
    PLoS One. 2024;19:e0311069.
    PubMed         Abstract available

  90. KITAMURA K, Arita M
    Evaluation of VP4-VP2 sequencing for molecular typing of human enteroviruses.
    PLoS One. 2024;19:e0311806.
    PubMed         Abstract available

  91. LIU C, Ma H, Wang X, Cui J, et al
    A comparative study of dynamic risk spillovers among financial sectors in China before and after the epidemic.
    PLoS One. 2024;19:e0314071.
    PubMed         Abstract available

  92. UDOH E, Okonkwo O, Omoregie G, Ura-Akubo V, et al
    Service quality in decentralized community-based Covid-19 antigen rapid diagnostic testing programmes in the Federal Capital Territory, Nigeria.
    PLoS One. 2024;19:e0310294.
    PubMed         Abstract available

  93. PARK S, Bangirana P, Mupere E, Baluku RI, et al
    Association of COVID-19-related perceptions and experiences with depression and anxiety in Ugandan caregivers of young children with malaria and iron deficiency: A cross-sectional study.
    PLoS One. 2024;19:e0314409.
    PubMed         Abstract available

  94. KOSTADINOV M, Zdravevski E, Lameski P, Coelho PJ, et al
    Forecasting air pollution with deep learning with a focus on impact of urban traffic on PM10 and noise pollution.
    PLoS One. 2024;19:e0313356.
    PubMed         Abstract available

  95. MAGHSOODI E, Hasanpour E, Soleimani F, Aghal M, et al
    Evaluation of anxiety level and the factors Affecting Anxiety in health care workers in Shahid Dr. Gholipour Hospital, Bukan, Iran during COVID-19 pandemic.
    PLoS One. 2024;19:e0264916.
    PubMed         Abstract available

  96. KE Y, Yang M, Xie Y
    An empirical research based on spatial-temporal evolution of high-quality tourism development in Fujian Province of China.
    PLoS One. 2024;19:e0315221.
    PubMed         Abstract available

  97. SAENGER TR, Kapstein EB, Sircar R
    Estimating the collapse of Afghanistan's economy using nightlights data.
    PLoS One. 2024;19:e0315337.
    PubMed         Abstract available

  98. SSEMATIMBA A, Malladi S, Bonney PJ, St Charles KM, et al
    Estimating the time of Highly Pathogenic Avian Influenza virus introduction into United States poultry flocks during the 2022/24 epizootic.
    PLoS One. 2024;19:e0310733.
    PubMed         Abstract available

  99. BOCCOLINI PMM, Boclin KLS, de Sousa IMC, Boccolini CS, et al
    Use of integrative and complementary practices in Brazil during the COVID-19 pandemic.
    PLoS One. 2024;19:e0311832.
    PubMed         Abstract available

  100. GABARRELL-PASCUET A, Coll-Planas L, Alias SB, Pascual RM, et al
    Reducing loneliness and depressive symptoms in older adults during the COVID-19 pandemic: A pre-post evaluation of a psychosocial online intervention.
    PLoS One. 2024;19:e0311883.
    PubMed         Abstract available

  101. D'SOUZA GC, Yingst JM, Krebs NM, Bordner C, et al
    Using the diffusion of innovations theory to understand factors associated with COVID-19 vaccination among tobacco users.
    PLoS One. 2024;19:e0309780.
    PubMed         Abstract available

  102. WAFUBWA RN, Soler-Hampejsek E, Muluve E, Osuka D, et al
    Adolescent school retention post COVID-19 school closures in Kenya: A mixed-methods study.
    PLoS One. 2024;19:e0315497.
    PubMed         Abstract available

  103. AN Q, Wu J, Chen WH
    Using the SEIQR model with epidemic amplifier effect to predict the final outbreak size of the COVID-19 in Dalian, Liaoning province, China.
    PLoS One. 2024;19:e0307239.
    PubMed         Abstract available

  104. SARAGOSA M, Goraya F, Nowrouzi-Kia B, Gohar B, et al
    A qualitative study examining stressors among Respiratory Therapists in Ontario amidst the COVID-19 pandemic.
    PLoS One. 2024;19:e0312504.
    PubMed         Abstract available

  105. POZO JI, Cabellos B, Perez Echeverria MDP
    Has the educational use of digital technologies changed after the pandemic? A longitudinal study.
    PLoS One. 2024;19:e0311695.
    PubMed         Abstract available

  106. ROBINSON JL, Kellner JD, Crotts J, Travassos G, et al
    Accuracy of the diagnosis of pneumonia in Canadian pediatric emergency departments: A prospective cohort study.
    PLoS One. 2024;19:e0311201.
    PubMed         Abstract available

  107. ARPPO A, Barker H, Parkkila S
    Bioinformatic characterization of ENPEP, the gene encoding a potential cofactor for SARS-CoV-2 infection.
    PLoS One. 2024;19:e0307731.
    PubMed         Abstract available

  108. KE T, Livingston M, Zhang Y, Pavlyshyn D, et al
    A longitudinal study of alcohol consumption among adults in Victoria, Australia during the COVID-19 pandemic.
    PLoS One. 2024;19:e0313599.
    PubMed         Abstract available

  109. MORITA S, Tokumasu K, Otsuka Y, Honda H, et al
    Phase-dependent trends in the prevalence of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) related to long COVID: A criteria-based retrospective study in Japan.
    PLoS One. 2024;19:e0315385.
    PubMed         Abstract available

  110. DAGNAW TE, Delie AM, Kassie TD, Berihun S, et al
    Knowledge, attitude, and practice towards COVID-19 and associated factors among students in Ethiopia: Systematic review and meta-analysis.
    PLoS One. 2024;19:e0314451.
    PubMed         Abstract available

  111. RAHMAN MM, Pradhan MR, Ghosh MK, Rahman MM, et al
    The impact of COVID-19 pandemic on fertility behaviour in Indian states: Evidence from the National Family Health Survey (2019/21).
    PLoS One. 2024;19:e0314800.
    PubMed         Abstract available

  112. VICKERS P, Adamo L, Alfano M, Clark C, et al
    Development of a novel methodology for ascertaining scientific opinion and extent of agreement.
    PLoS One. 2024;19:e0313541.
    PubMed         Abstract available

  113. SUGIURA Y, Shimizu K, Takahashi T, Ueno S, et al
    Amino acid T25 in the substrate-binding domain of SARS-CoV-2 nsp5 is involved in viral replication in the mouse lung.
    PLoS One. 2024;19:e0312800.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A


  114. Correction for Rockey et al., Ventilation does not affect close-range transmission of influenza virus in a ferret playpen setup.
    Proc Natl Acad Sci U S A. 2024;121:e2424158121.
    PubMed        


    Vaccine

  115. WILLIAMS JTB, Ritger C, Holliman BD, Huebschmann AG, et al
    Staff and caregivers' perceptions of digital storytelling to increase influenza vaccine confidence in an urban safety-net healthcare system.
    Vaccine. 2024;45:126572.
    PubMed         Abstract available

  116. XIA M, Huang P, Vago FS, Jiang W, et al
    Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza viruses elicited high HA1-specific antibody responses and protected mice against mortality caused by influenza virus challenges.
    Vaccine. 2024 Dec 7:126585. doi: 10.1016/j.vaccine.2024.126585.
    PubMed         Abstract available

  117. KAPLAN BS, Souza CK, Kimble JB, Brand MW, et al
    A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine.
    Vaccine. 2024 Dec 6:126574. doi: 10.1016/j.vaccine.2024.126574.
    PubMed         Abstract available

  118. MARCHESE AM, Beyhaghi H, Rousculp MD, Huang V, et al
    Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
    Vaccine. 2025;44:126569.
    PubMed         Abstract available

  119. FILIMONOVIC J, Stosic M, Gazibara T, Dotlic J, et al
    The trend in national childhood immunization program coverage throughout Serbian communities in Kosovo and Metohija from 2003 to 2022: pre-COVID-19 period vs. COVID-19 pandemic.
    Vaccine. 2025;44:126576.
    PubMed         Abstract available

  120. PICHE-RENAUD PP, Drover SSM, Austin PC, Morris SK, et al
    COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study.
    Vaccine. 2024 Nov 30:126539. doi: 10.1016/j.vaccine.2024.126539.
    PubMed         Abstract available

  121. HARTEVELD LM, van Leeuwen LM, Euser SM, Smit LJ, et al
    Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands.
    Vaccine. 2025;44:126541.
    PubMed         Abstract available

  122. COSMA C, Radi A, Cattano R, Zanobini P, et al
    Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A scoping review of the literature.
    Vaccine. 2024;44:126559.
    PubMed         Abstract available

  123. FLORES D, Luna EM
    The effectiveness of vaccines against COVID-19 in Mexico: A time series approach.
    Vaccine. 2024;44:126565.
    PubMed         Abstract available

  124. THIEM VD, Anh DD, Ha VH, Van Thom N, et al
    Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
    Vaccine. 2024;44:126542.
    PubMed         Abstract available

  125. WANG Q, Yang L, Li L, Xiu S, et al
    Investigating parental perceptions of respiratory syncytial virus (RSV) and attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.
    Vaccine. 2024;44:126570.
    PubMed         Abstract available

  126. GEMANDER N, Kemlin D, Depickere S, Kelkar NS, et al
    COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients.
    Vaccine. 2024;44:126544.
    PubMed         Abstract available

  127. BLUKACZ A, Obach A, Vasquez P, Campana C, et al
    Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and middle-income countries: A systematic review of qualitative evidence and thematic synthesis.
    Vaccine. 2024;44:126546.
    PubMed         Abstract available

  128. AMODIO D, Angelidou A, Cotugno N, Sherman AC, et al
    Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference.
    Vaccine. 2024;43.
    PubMed         Abstract available

  129. DE LIMA EDS, Antunes MOB, de Souza JS, Jones MH, et al
    Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study.
    Vaccine. 2025;44:126550.
    PubMed         Abstract available

  130. DEAN NE, Halloran ME, Zarnitsyna VI
    Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease.
    Vaccine. 2024;43.
    PubMed         Abstract available

  131. LEE M, Qin C, Lee Y, Deng J, et al
    COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron surge in South Korea and China.
    Vaccine. 2024;43.
    PubMed         Abstract available

  132. DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al
    Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents.
    Vaccine. 2024;43.
    PubMed         Abstract available

  133. MEELDIJK A, Vandeberg L, Akkermans R, Hautvast J, et al
    How text message reminders increase COVID-19 booster vaccine uptake: Two randomized controlled trials.
    Vaccine. 2024;43.
    PubMed         Abstract available

  134. LOCKMAN A, Callaghan T, Blackburn CC, Colwell B, et al
    Vaccine spillover effects in Africa: A cross-national study of vaccine spillover and confidence in Kenya, Nigeria, and South Africa.
    Vaccine. 2024;43.
    PubMed         Abstract available

  135. JASTORFF A, Gymnopoulou E, Salas J, Merrall E, et al
    Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
    Vaccine. 2024;43.
    PubMed         Abstract available

  136. REGAN AK, Couture MC, Callaghan T, Agnew B, et al
    Modification and validation of a vaccine hesitancy scale for adolescent COVID-19 vaccination.
    Vaccine. 2024;43.
    PubMed         Abstract available

  137. LOPEZ-MACIAS C, Torres M, Armenta-Copca B, Wacher NH, et al
    Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
    Vaccine. 2024;43.
    PubMed         Abstract available

  138. GWAK E, Choe SA, Bolormaa E, Choe YJ, et al
    Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea.
    Vaccine. 2024;43.
    PubMed         Abstract available

  139. WILLIAMS E, Echeverri Tribin F, Carreno JM, Krammer F, et al
    Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.
    Vaccine. 2024;43.
    PubMed         Abstract available

  140. MATTES F, Dratva J, Schmelzer S, Wagner A, et al
    The association between service experience in vaccination centers and expectation confirmation as a driver of future vaccination intentions: Results from a survey among users of a Swiss mass COVID-19 vaccination center.
    Vaccine. 2024;43.
    PubMed         Abstract available

  141. AGUIRRE-CAMACHO A, Hidalgo B, Rash JA
    Exposure to objective/sensationalist information moderates associations between psychological factors and COVID-19 anti-vaccination attitudes: An experimental study.
    Vaccine. 2024;43.
    PubMed         Abstract available

  142. HAEBERER M, Lopez-Ibanez de Aldecoa A, Seabroke S, Ramirez Agudelo JL, et al
    Economic burden of children hospitalized with respiratory syncytial virus infection in Spain, 2016-2019.
    Vaccine. 2025;43.
    PubMed         Abstract available

  143. DENG Y, Hayes KN, Zhao Y, Chachlani P, et al
    Variation in the time to complete the primary COVID-19 vaccine series by race, ethnicity, and geography among older US adults.
    Vaccine. 2024;43.
    PubMed         Abstract available

  144. STEFFENS MS, Bolsewicz KT, King C, Bullivant B, et al
    Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic.
    Vaccine. 2024;43.
    PubMed         Abstract available

  145. LE MARCHAND C, Singson JRC, Clark A, Shah D, et al
    Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California.
    Vaccine. 2024;43.
    PubMed         Abstract available

  146. DELARUELLE K, Lermytte E, Bockstal M, Vuolanto P, et al
    Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of preventive practices.
    Vaccine. 2024;43.
    PubMed         Abstract available

  147. KIM SA, Maeda M, Murata F, Fukuda H, et al
    Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study.
    Vaccine. 2024;43.
    PubMed         Abstract available

  148. MOHD HISHAM AA, Mat Yassim AS, Suppian R, Azlan M, et al
    Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.
    Vaccine. 2024;42:126471.
    PubMed         Abstract available

  149. CHARLAND K, Quach C, Papenburg J, Pierce L, et al
    Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada.
    Vaccine. 2024;43.
    PubMed         Abstract available

  150. HOFSTETTER AM, Klein EJ, Strelitz B, Selvarangan R, et al
    On-time childhood vaccination before and during the COVID-19 pandemic in seven communities: Findings from the New Vaccine Surveillance Network.
    Vaccine. 2024;42:126455.
    PubMed         Abstract available

  151. WHITE TM, Lazarus JV, Rabin KH, Ratzan SC, et al
    Emerging global patterns of COVID-19 vaccine information fatigue in 23 countries in 2023.
    Vaccine. 2024;42:126475.
    PubMed         Abstract available

  152. EBERHARDT J, Al-Qerem W, Ling J
    Comparing COVID-19 booster vaccine acceptance in the United Kingdom, Germany, Austria, and Jordan: The role of protection motivation theory, conspiracy beliefs, social media use and religiosity.
    Vaccine. 2024;42:126474.
    PubMed         Abstract available

  153. MCGREGOR R, Paterson A, Lavender B, Hooker C, et al
    The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.
    Vaccine. 2024;42:126482.
    PubMed         Abstract available

  154. LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
    Exploring the delivery of adult vaccination outside of primary care settings: A mixed methods scoping review.
    Vaccine. 2024;42:126458.
    PubMed         Abstract available

  155. HO TC, Chuang SC, Hung KC, Chang CC, et al
    Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination.
    Vaccine. 2024;42:126470.
    PubMed         Abstract available

  156. LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
    Exploring the attitudes and practices of adult service users and providers towards vaccination in non-primary care settings: A mixed methods scoping review.
    Vaccine. 2024;42:126472.
    PubMed         Abstract available

  157. JORDAN E, Jenkins V, Silbernagl G, Chavez MPV, et al
    A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.
    Vaccine. 2024;42:126427.
    PubMed         Abstract available

  158. NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al
    Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore.
    Vaccine. 2024;42:126462.
    PubMed         Abstract available

  159. DARKO DM, Seaneke SK, Karikari-Boateng E, Nkansah E, et al
    Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study.
    Vaccine. 2024;42:126460.
    PubMed         Abstract available

  160. AB RAHMAN N, King TL, Peariasamy KM, Sivasampu S, et al
    Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study.
    Vaccine. 2024;42:126465.
    PubMed         Abstract available

  161. SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al
    Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an integrated health system.
    Vaccine. 2024;42:126440.
    PubMed         Abstract available

  162. WICKLINE MM, Carpenter PA, Harris JR, Iribarren SJ, et al
    Vaccine hesitancy and routine revaccination among adult HCT survivors in the United States: A convergent mixed methods analysis.
    Vaccine. 2024;42:126374.
    PubMed         Abstract available

  163. HARRACHE A, Saker K, Mokdad B, Generenaz L, et al
    Anti-RBD IgG dynamics following infection or vaccination.
    Vaccine. 2024;42:126464.
    PubMed         Abstract available

  164. MA SH, Chen TL, Ou WF, Chao WC, et al
    The risk of postherpetic neuralgia in COVID-19 vaccination-associated herpes zoster: A retrospective cohort study using TriNetX.
    Vaccine. 2024;42:126451.
    PubMed         Abstract available

  165. EVIATAR T, Ziv A, Oved A, Miller-Barmak A, et al
    Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study.
    Vaccine. 2024;42:126426.
    PubMed         Abstract available

  166. NAZARENO AL, Newall AT, Muscatello DJ, Hogan AB, et al
    Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia.
    Vaccine. 2024;42:126418.
    PubMed         Abstract available

  167. SANO K, Kurosawa T, Horikawa K, Kimura Y, et al
    Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan.
    Vaccine. 2024;42:126452.
    PubMed         Abstract available

  168. NUZHATH T, Colwell B, Callaghan T, Hotez P, et al
    Pediatric COVID-19 vaccine hesitancy among pregnant and post-partum women: A mixed-method study.
    Vaccine. 2024;42:126420.
    PubMed         Abstract available

  169. EIDEN AL, Drakeley S, Modi K, Mackie D, et al
    Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey.
    Vaccine. 2024;42:126437.
    PubMed         Abstract available

  170. COCKERILL R, Horney JA, Penta SC, Silver A, et al
    Factors associated with COVID-19 vaccination or intent to be vaccinated across three U.S. states.
    Vaccine. 2024;42:126457.
    PubMed         Abstract available

  171. TOP KA, Shulha HP, Muller MP, Valiquette L, et al
    Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study.
    Vaccine. 2024;42:126445.
    PubMed         Abstract available

  172. HSIEH HC, Chen CC, Liu WC, Wu SC, et al
    Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice.
    Vaccine. 2024;42:126448.
    PubMed         Abstract available

  173. SEDAGHAT M, Karami B, Najafi F, Shadmani FK, et al
    Gender differences in adverse effects following the second dose of AstraZeneca COVID-19 vaccine: a cross-sectional study among healthcare workers.
    Vaccine. 2024;42:126424.
    PubMed         Abstract available

  174. DOYON-PLOURDE P, Farley R, Krishnan R, Tunis M, et al
    Direct quantitative comparison of benefits and risks of COVID-19 vaccines used in National Immunization Technical Advisory Groups Guidance during the first two years of the pandemic.
    Vaccine. 2024;42:126406.
    PubMed         Abstract available

  175. VYSE A, Wright H, Begier E
    Estimating adult accident and emergency attendances in English hospitals attributed to respiratory syncytial virus.
    Vaccine. 2024;42:126412.
    PubMed         Abstract available

  176. PASCOE KM, Bishop S, Ci X, Ramirez M, et al
    Factors that shape COVID-19 pediatric vaccine decision-making in rural agricultural communities: A qualitative study.
    Vaccine. 2024;42:126389.
    PubMed         Abstract available

  177. HOJO-SOUZA NS, de Castro JT, Rivelli GG, Azevedo PO, et al
    SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern.
    Vaccine. 2024;42:126394.
    PubMed         Abstract available

  178. ALANSARI KDH, Buhl C, Thabit AK, Badr AF, et al
    Validation of the Arabic translation of the vaccination attitudes examination (VAX) scale.
    Vaccine. 2024;42:126411.
    PubMed         Abstract available

  179. EARP M, Meng L, Black CL, Carter RJ, et al
    Using regression tree analysis to examine demographic and geographic characteristics of COVID-19 vaccination trends over time, United States, May 2021-April 2022, National Immunization Survey Adult COVID Module.
    Vaccine. 2024;42:126372.
    PubMed         Abstract available

  180. PATRICK-SMITH M, Emary K, Hodgson SH, Thomas TM, et al
    Roles and responsibilities of participants, researchers, and the media in the communication of vaccine trials: Experience from the United Kingdom's first COVID-19 vaccine trial.
    Vaccine. 2024;42:126391.
    PubMed         Abstract available

  181. LYU X, Liu X, Hong H
    Validation of the Chinese version of the vaccine conspiracy beliefs scale during COVID-19 pandemic and its correlates.
    Vaccine. 2024;42:126395.
    PubMed         Abstract available

  182. SOTOODEH A, Hedberg P, Granath F, Alfven T, et al
    Sociodemographic determinants of COVID-19 vaccination in adolescents in Stockholm, Sweden.
    Vaccine. 2024;42:126388.
    PubMed         Abstract available

  183. ENGLAND A, Sung J, Deulofeu M, Soler LF, et al
    Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax(R)) by HIPRA.
    Vaccine. 2024;42:126386.
    PubMed         Abstract available

  184. BERNADIN O, Cochin M, Driouich JS, Laprie C, et al
    Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer Programme.
    Vaccine. 2024;42:126378.
    PubMed         Abstract available

  185. AVERIN A, Sato R, Begier E, Gessner BD, et al
    Annual public health and economic burden of medically attended respiratory syncytial virus illnesses among US adults.
    Vaccine. 2024;42:126323.
    PubMed         Abstract available

  186. LAEMMLE-RUFF I, Fryk JJ, Shenton P, Clothier HJ, et al
    Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021-2023.
    Vaccine. 2024;42:126368.
    PubMed         Abstract available

  187. WEE LE, Malek MIBA, Tan J, Chiew C, et al
    Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.
    Vaccine. 2024;42:126356.
    PubMed         Abstract available

  188. FOTAKIS EA, Picasso E, Sacco C, Petrone D, et al
    Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023-March 2024).
    Vaccine. 2024;42:126375.
    PubMed         Abstract available

  189. PRY JM, McCullough K, Lai KW, Lim E, et al
    Defining long COVID using a population-based SARS-CoV-2 survey in California.
    Vaccine. 2024;42:126358.
    PubMed         Abstract available

  190. KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al
    Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study.
    Vaccine. 2024;42:126320.
    PubMed         Abstract available

  191. SHIU EYC, Cheng SMS, Martin-Sanchez M, Au NYM, et al
    Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine.
    Vaccine. 2024;42:126317.
    PubMed         Abstract available

  192. VAN HEESBEEN R, Bastian AR, Omoruyi E, Rosen J, et al
    Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.
    Vaccine. 2024;42:126273.
    PubMed         Abstract available

  193. CHANG JY, Chang M, Huang S, Bosco J, et al
    COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.
    Vaccine. 2024;42:126260.
    PubMed         Abstract available

  194. CHUN J, Yoon D, Nowakowska A, Lee HD, et al
    Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern.
    Vaccine. 2024;42:126355.
    PubMed         Abstract available

  195. CANETTI M, Barda N, Lustig Y, Weiss-Ottolenghi Y, et al
    Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers.
    Vaccine. 2024;42:126308.
    PubMed         Abstract available

  196. BLASCO A, Royuela A, Garcia-Gomez S, Gomez-Lozano N, et al
    Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome.
    Vaccine. 2024;42:126305.
    PubMed         Abstract available


    Virus Res

  197. KOMAMI M, Komu JG, Ishiguro Y, Sasaki M, et al
    Detection of antibodies against H5 subtype highly pathogenic avian influenza viruses in multiple raccoons in Tokachi District, Hokkaido, Japan, from 2022 to 2023.
    Virus Res. 2024 Dec 15:199515. doi: 10.1016/j.virusres.2024.199515.
    PubMed         Abstract available

  198. MAO B, Le-Trilling VTK, Tang H, Hu J, et al
    Diphyllin elicits a doubled-pronged attack on the entry of SARS-CoV-2 by inhibiting cathepsin L and furin.
    Virus Res. 2024;350:199485.
    PubMed         Abstract available

  199. GIRMA A
    Biology of human respiratory syncytial virus: Current perspectives in immune response and mechanisms against the virus.
    Virus Res. 2024;350:199483.
    PubMed         Abstract available

  200. KUROSE M, Yamamoto A, Elsayed AMA, Lawal-Ayinde BM, et al
    Viral coexistence and insertional mutations in the ORF8 region of SARS-CoV-2: A possible mechanism of nucleotide insertion.
    Virus Res. 2024;350:199478.
    PubMed         Abstract available

  201. NO JS, Noh JY, Lee CY, Kim IH, et al
    Dynamics of SARS-CoV-2 variants during the XBB wave in the Republic of Korea.
    Virus Res. 2024;350:199471.
    PubMed         Abstract available

Comments

Popular posts from this blog

#USA, Two more #human cases of #H5N1 #birdflu reported in #California

Two cases of bird flu have been reported in San Joaquin County, California, local health officials said. According to a press release issued Friday and reported by the Sacramento Bee , health officials with San Joaquin County Public Health Services said both cases were farm workers who were exposed to infected animals . Both people are showing mild symptoms and are recovering, officials said, adding that there are 34 total confirmed cases across California. In a warning posted on Facebook, health officials said bird flu was “spreading in several farms such as poultry and cattle” and urged residents to take precautions to prevent the spread of the disease. Precautions include the use of protective equipment when handling poultry, dairy cattle or other animals that may be infected, and when handling raw and unpasteurized milk. (...) There are currently 60 confirmed cases of bird flu in the country . While most of the cases are in California , other states with confirmed cases include Col...

Viral #sepsis: #diagnosis, clinical #features, #pathogenesis, and #clinical considerations

Abstract Sepsis , characterized as life-threatening organ dysfunction resulting from dysregulated host responses to infection , remains a significant challenge in clinical practice . Despite advancements in understanding host-bacterial interactions , molecular responses, and therapeutic approaches, the mortality rate associated with sepsis has consistently ranged between 10 and 16%. This elevated mortality highlights critical gaps in our comprehension of sepsis etiology. Traditionally linked to bacterial and fungal pathogens, recent outbreaks of acute viral infections , including Middle East respiratory syndrome coronavirus ( MERS-CoV ), influenza virus, and severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ), among other regional epidemics, have underscored the role of viral pathogenesis in sepsis, particularly when critically ill patients exhibit classic symptoms indicative of sepsis. However, many cases of viral-induced sepsis are frequently underdiagnosed because standar...

Rapid #Surge of #Reassortant A(#H1N1) #Influenza Viruses in Danish #Swine and their #Zoonotic Potential

 Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.12.11.627926v1?rss=1  Abstract In 2018, a single detection of a novel reassortant swine influenza A virus (swIAV) was made in Denmark . The hemagglutinin (HA) of the virus was from the H1N1 pandemic 2009 (H1N1pdm09) lineage and the neuraminidase (NA) from the H1N1 Eurasian avian-like swine lineage (H1N1av). By 2022, the novel reassortant virus (H1pdm09N1av) constituted 27 % of swIAVs identified through the Danish passive swIAV surveillance program. Sequencing detected two H1pdm09N1av genotypes ; Genotype 1 contained an internal gene cassette of H1N1pdm09 origin , Genotype 2 differed by carrying an NS gene segment of H1N1av origin . The internal gene cassette of Genotype 2 became increasingly dominant, not only in the H1pdm09N1av population, but also in other Danish enzootic swIAV subtypes . Phylogenetic analysis of the HA genes from H1pdm09N1av viruses revealed a monophyletic source , a higher substitution rat...